Dr Mussaad Al-Razouki

Dr Mussaad Al-Razouki

Chief Business Development Officer,Kuwait Life Sciences Company

Dr. Razouki has over 15 years of experience in venture capital and private equity investment with a focus on healthcare and technology, shifting from an excellence in clinical practice and research to the management and financing of healthcare and education systems. A graduate of Columbia Business School, Dr. Razouki is the first ever Arab national to receive an MBA with a focus on Healthcare Management and Finance. An Oral and Maxillofacial surgeon by training, Dr. Razouki has completed clinical rotations at New York Presbyterian Hospital of Columbia University Medical Center, Harlem Hospital, Cleveland University Hospital of Case Western Reserve University and Mass General Hospital of Harvard University. Dr. Razouki graduated with Cum Laude Honors from Creighton University with a Bachelors in Biology (Ethology) and TPP (Theology, Philosophy and Political Science).

In 2007, Dr. Razouki joined the world’s largest and oldest strategic consulting firms, Booz Allen Hamilton, which at the time was operating in over 100 countries across six continents with four billion dollars in revenue. Dr Razouki had the honor of working with all six GCC Minister’s of health and completed health and public sector projects across the GCC, Lebanon and Egypt.

In 2015, Dr. Razouki was the first ever Kuwaiti doctor to complete the “Reforming of Public Systems: Health, Higher Education and Finance” Executive Education course at the prestigious Grande École, Paris Institute of Political Studies (“Sciences Po”).

Dr. Razouki was also presented with the Kuwait e-Award for best eHealth application by His Highness Sheikh Sabah Al Ahmed Al Sabah, the Emir of Kuwait. Dr. Razouki was also selected by Stanford Medicine as part of a group of 20 global authors to write a chapter on digital health investing in the upcoming Springer published book: Digital Health: Scaling Healthcare to the World. He is the only author from the Arab World.

During 2015, Dr. Razouki was also an Industry Expert Board Member at Al Ayadi Al Baytha Health Company, a 50 mn USD fully owned company of Al Khabeer Capital, which is one of Saudi Arabia’s largest and most active private equity investors with over three billion dollars of assets under management. Dr. Razouki worked together with the turnaround team at Al Khabeer and the asset’s management to unlock unrealized value in one of Saudi Arabia’s fastest growing medical services companies.

In 2016, Dr. Razouki was selected by the Abdul Rahman Al Sumait Award Executive Committee to represent the science community in Kuwait and present at the first ever meeting of the committee. The Committee is co-chaired by His Excellency Sheikh Sabah Khalid Al Hamad Al Sabah, Kuwait’s Minister of Foreign Affairs and Mr. Bill Gates. At one million USD it is the largest science prize awarded in for scientific achievement in Africa. Dr. Razouki was also nominated as one of the top five venture capital investors in the Middle East and North Africa by Arabian Business. Dr. Razouki also won two awards at the seventh annual Middle East Healthcare Leadership Awards for both Middle East Public Private Partnership of the Year for the Jaber Hospital PPP Sustainable Hospital Project as well as Healthcare Entrepreneur of the Year.

In 2016, Dr. Razouki was also selected to participate in the prestigious World Economic Forum Global Health and Healthcare Community Meeting as part of the Future Trends in Health Task Force which was Chaired by Dr. Melanie Walker, Advisor to the President of the World Bank, Dr. Jim Young Kim. Dr. Razouki was the only participant from Kuwait and had the honor of having seven out the 10 final key technological trends and themes accepted in the final outcome report of the forum.

Dr. Razouki has also been invited to lecture at top universities and events including Cambridge University, Columbia University, Harvard University and the Cleveland Clinic. Dr. Razouki has also spoken at the World Economic Forum on the Middle East (Dead Sea, 2017) and the World Bank: Youth, Technology and Finance Conference in Algiers during 2018.

In 2017, Dr. Razouki was appointed to the Advisory Board of Popular Science Magazine. An outlet for eminent scientists such as Charles Darwin and Thomas Edison’s writings and ideas in the 19th century, Popular Science is the most prestigious science magazine in the world and was first launched in 1872.

Dr. Razouki was also appointed by the Kuwait Foundation for the Advancement of Sciences to the Board of Trustees of the Jaber Al Ahmed Center for Molecular Imaging and Nuclear Medicine (JAC), the MENA region’s first center of excellence and Type II facility dedicated to the production of common radiopharmaceuticals for applications in positron emission tomography. Dr. Razouki is also Chairman of the Executive Committee.

In 2018, Dr. Razouki was also recognized as one of the top 100 Leaders Who Inspire in an inaugural book on Kuwait developed in coordination with the United National Development Program (UNDP).

Dr. Razouki has also contributed a chapter on Growth Hacking Healthcare, as part of the upcoming Spring published book: Digital Health Entrepreneurship to be published in late 2018. He is the only contributor from the Arab World.

Dr. Razouki is the current Chief Business Development Officer of Kuwait Life Sciences Company (KLSC) where he is part of a team that manages over 100 million dollars in assets under management including local, regional and international investments on behalf of the Kuwait Investment Authority, the sovereign wealth fund of Kuwait. Dr. Razouki is a regional thought leader within the Middle East life sciences industry and has championed the building of strong pillars of the local life sciences ecosystem including the region’s premiere pharmaceutical licensing and distribution platform; NewBridge - a 50 mn USD revenue company operating across all 22 MENA countries including Iraq, Iran and Turkey as well as South Africa, Clinart – the region’s top Clinical Research Organization (CRO) and host of the first ever Phase II Clinical Trial in the history of Kuwait at the Dasman Diabetes Institute, eCore – the region’s top active pharmaceutical ingredients licensor and distributor, the Life Sciences Academy – the region’s first ever training and development company focused on the healthcare and life sciences industry as well as Innomedics – one of Kuwait’s top medical device distribution companies that pioneered the distribution of personalized digital health products in the region.

At KLSC, Dr. Razouki and his team have invested and co-invested with some of the world’s top life science venture capital funds including, New Leaf Venture Partners in New York, Wellington Partners in Munich and Kearny Venture Partners and Presidio Partners both of which are based in San Francisco. Notable investment direct and indirect investment include: CRISPR Therapeutics - a leading personalized genomic medicine company based in Cambridge, Massachusetts (NASDAQ: CRSP), iRhythm Technologies, based in San Francisco, which closed 56% above its listed stock price on the first day of its IPO (NASDAQ: IRTC), Quanta Fluid Solutions – one of the world’s first home hemodialysis manufacturers, Median Technologies – a leading global provider of medical imaging solutions, especially in the field of oncology based in France (EPA: ALMDT) and SuperSonic Imagine – a leading global provider of medical ultrasound solutions also based in France (EPA: SSI)

Dr. Razouki is also a former advisor to the central Kuwaiti government where he worked with senior government leaders during the administration of HE the Prime Minister, Sheikh Naser Al Mohammad Al Sabah and Deputy Prime Minister for Economic Affairs, Sheikh Ahmed Al Fahad Al Sabah on both Healthcare, Education and Entrepreneurial reforms as part of Kuwait’s 100 billion dollar Development Plan. Dr. Razouki continues to work closely with the Council of Minister’s of Kuwait and is currently advising the government on the development of the Sabah Al Ahmad National Genome Center together with the Kuwait Foundation for the Advancement of Sciences, a National Pharmaceutical Quality Control Laboratory, and the 1 bn USD Jaber Hospital project, a 1,168 facility which will be the largest single healthcare structure in the Middle East.